A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors is a phase 1/2 interventional study registered as NCT07070232 by BioNTech SE, with 1438 participants planned, started 2025-08-12 and due to reach its primary completion in 2028-03. Interventions recorded: BNT326, Pumitamig, Itraconazole and Paroxetine.